The following trials have been completed: 

I5T-MC-AACG – Assessment of Safety, Tolerability and Efficacy of LY3002813 Alone and in Combination with LY3202626 in Early Symptomatic Alzheimer’s Disease – Mild Cognitive Impairment MCI to Mild Alzheimer’s Disease

Eisai E2609-G000-301 – A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study with an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects with Early Alzheimer’s Disease. (Closed for screening) – Mild Cognitive Impairment MCI to Mild Alzheimer’s Disease.

Tetra – BPN14770-CNS-201 – A Randomized, Double-blind, Placebo-controlled, 3-arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients with Early Stages Alzheimer’s Disease – Mild Cognitive Impairment MCI to Mild Alzheimer’s Disease

Acadia045 – ACP-103-045 – A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis (Hallucinations and/or Delusions) – Symptoms of Psychosis for Any Related Diagnosis of Dementia

Avanir 17-AVP-786-305 – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo, Parallel-Design Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (deudextromethorpan hydrobromide [d6-DM / quinidine sulfate [Q]) for the Treatment of Agitation in Patients with Dementia of the Alzheimer’s Type. Agitation in Alzheimer’s Disease

Avanir 15-AVP-786-303 – A Phase 3, Multicenter, Long-Term, Extension Study of the Safety and Efficacy of AVP-786 (deuterated [d6]- destromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q] for the treatment of Agitation in Patients with Dementia of the Alzheimer’s Type. Open Label for Agitation in Alzheimer’s Disease

Novartis CCNP520A2202J – A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer’s Disease (AD) – Preventive study

Biogen 221AD302 – A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer’s Disease. Mild Cognitive Impairment MCI to Mild Alzheimer’s Disease

CREAD BN 29552 – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety of crenezumab in Patients with Prodromal to Mild Alzheimer’s Disease. Mild Cognitive Impairment MCI to Mild Alzheimer’s Disease

Acadia ACP-103-033 – A 52 week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects with Alzheimer’s Disease.

Acadia ACP-103-032 – Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects with Alzheimer’s Disease.

Eli Lilly I8D-MC-AZET – A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer’s Disease Dementia (The DAYBREAK Study). Mild Cognitive Impairment MCI to Mild Alzheimer’s Disease

Avanir 15-AVP-786-301 – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of AV-786 (deuterated [d6] – dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q] for the Treatment of Agitation in Patients with Dementia of the Alzheimer’s Type.

“A Multicenter, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Short-Term Plasma Exchange Followed by Long-Term Plasmapheresis with Infusion of Albutein® Combined with Flebogammadif® in Patients with Mild-Moderate Alzheimer’s Disease” (the “Study”), bearing Protocol No. IG 1002 (AMBAR)

Study number: 14863A Protocol title: “Randomised, double-blind, parallel-group, placebo-controlled study of Lu AE58054 in patients with mild-moderate Alzheimer’s disease treated with an acetylcholinesterase inhibitor; Study 3”

Protocol H8A-MC-LZAX “ Effect of Passive Immunization on the Progression of Mild Alzheimer’s Disease: Solanezumab (LY2062430) versus Placebo” (EXPEDITION-3)

ELND005-AG201 “A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients with Moderate to Severe Alzheimer’s Disease”

“A Phase 2, randomized, double-dummy, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-923 (dextromethorphan/quinidine) for the treatment of symptoms of agitation in patient with Alzheimer’s disease”

An open label, multicenter study, evaluating the safety and imaging characteristics of F-AV-1451 in cognitively healthy volunteers, subjects with Mild Cognitive Impairment, and subjects with Alzheimer's disease.
Avid Radiopharmaceuticals

A Randomized, 18-week, placebo-controlled, double-blind, parallel group study of the safety and efficacy of PF-052212377 (SAM-760) in subjects with mild-to-moderate Alzheimer's disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil.
Pfizer Pharmaceuticals

A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Eisai Inc.

A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Elan Pharma International Limited

= Trial is Closed